Innoviva earnings release, May 6, 2026

Innoviva, Inc. (INVA) · Form 8-K, Item 2.02 · Filed · SEC filing

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Generated $58.6 million in revenue from resilient royalties portfolio

Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth

Significant value created across strategic healthcare asset portfolio

BURLINGAME, Calif. – May 6, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the

“Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.

“We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales.”

“We also remained active in executing our capital allocation priorities, including increased activity under our $125 million share repurchase program, underscoring our confidence in Innoviva’s long-term value proposition. Innoviva’s strong track record across its operating and strategic healthcare assets, coupled with significant cash resources and durable royalty inflows, positions us well for accretive capital deployment and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld.

Financial Highlights for the First Quarter of 2026

Key Business and R&D Highlights

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva

Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®

/BREO®

ELLIPTA® and ANORO®

ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA®

(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO®

(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of

Acinetobacter baumannii-calcoaceticus, XERAVA®

(eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA

- 2 -

(ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and

NUZOLVENCE®

(zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg.

For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Royalty revenue, net (1)55,16757,807
Revenue:Net product sales41,37130,279
Revenue:License and other revenue1,456546
Revenue:Total revenue97,99488,632
Revenue:Cost of products sold (inclusive of amortization of inventory fair value adjustments)15,6078,842
Revenue:Amortization of acquired intangible assets6,5546,475
Revenue:Gross profit75,83373,315
Operating expenses:Selling, general and administrative32,43827,491
Operating expenses:Research and development5,2414,396
Operating expenses:Total operating expenses37,67931,887
Operating expenses:Income from operations38,15441,428
Operating expenses:Changes in fair values of equity method investments, net157,650-13,549
Operating expenses:Changes in fair values of equity and long-term investments, net33,575-65,299
Operating expenses:Interest and dividend income10,9874,538
Operating expenses:Interest expense-5,437-4,711
Operating expenses:Other expense, net-366-996
Operating expenses:Income (loss) before income taxes234,563-38,589
Operating expenses:Income tax expense-47,968-7,995
Operating expenses:Net income (loss)186,595-46,584
Net income (loss) per share:Basic2.52-0.74
Net income (loss) per share:Diluted2.22-0.74
Shares used to compute net income (loss) per share:Basic74,16062,709
Shares used to compute net income (loss) per share:Diluted84,84962,709

Balance Sheet

December 31, — (unaudited) (in thousands)

March 31, – 2026December 31, – 2025
AssetsCash and cash equivalents603,085550,941
AssetsRoyalty and product sale receivables92,62893,317
AssetsInventory38,84339,172
AssetsPrepaid expense and other current assets29,22128,358
AssetsCurrent portion of ISP Fund investments8,84615,727
AssetsProperty and equipment, net2,1421,555
AssetsEquity method and equity and long-term investments764,454598,223
AssetsCapitalized fees52,68256,138
AssetsRight-of-use assets10,65210,929
AssetsGoodwill17,90517,905
AssetsIntangible assets175,602182,156
AssetsOther assets40,52740,744
AssetsTotal assets1,836,5871,635,165
Liabilities and stockholders’ equityOther current liabilities32,65043,808
Liabilities and stockholders’ equityAccrued interest payable2311,618
Liabilities and stockholders’ equityDeferred revenue3,6774,270
Liabilities and stockholders’ equityConvertible senior notes, due 2028, net258,095257,731
Liabilities and stockholders’ equityDeferred tax liabilities, net72,83131,793
Liabilities and stockholders’ equityIncome tax payable, long term58,34557,013
Liabilities and stockholders’ equityOther long term liabilities69,10366,091
Liabilities and stockholders’ equityStockholders’ equity1,341,6551,172,841
Liabilities and stockholders’ equityTotal liabilities and stockholders’ equity1,836,5871,635,165

Cash Flow

Three Months Ended March 31, — (unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net cash provided by operating activities35,28248,617
Net cash provided by (used in) investing activities37,008-34,674
Net cash provided by (used in) financing activities-20,146183
Net change52,14414,126
Cash and cash equivalents at beginning of period550,941304,964
Cash and cash equivalents at end of period603,085319,090
Full release

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation

Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of

RELVAR®

/BREO®

ELLIPTA®, ANORO®

ELLIPTA®, GIAPREZA®,

XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and... (truncated) potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on

Form

10-K for the year ended December 31, 2025 and Quarterly Reports on Form

10-Q, which are on file with the Securities and Exchange

Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

- 3 -

INNOVIVA, INC.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

- 4 -

INNOVIVA, INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

INNOVIVA, INC.

Cash Flows Summary

(in thousands)

(unaudited)

- 5 -

Contacts

Investor Relations (Internal):

Eleanor Barisser

Director, Investor Relations and Corporate Communications

Eleanor.barisser@inva.com

Investors and Media:

Argot Partners

(212)

600-1902 innoviva@argotpartners.com

- 6 -

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Innoviva earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.